Pharma shares extend rally; Dr Reddy's, Sun Pharma hit 52-week high
In past 14 trading days, Nifty Pharma index outperformed the market by surging 15% as compared to 2.3% rise in Nifty 50 index.
 "Pharma shares extend rally; Dr Reddy's, Sun Pharma hit 52-week high")
premium
Shares of pharmaceutical companies continued their upward journey with Nifty Pharma index quoting higher for 11 out of past 14 trading days on the National Stock Exchange (NSE).
Sun Pharmaceutical Industries, Dr Reddys Laboratories, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Abbott India, Merck, Sanofi India and GlaxoSmithKline Pharmaceuticals were among 11 stock that hit their respective 52-week highs on Monday.
Hikal, Poly Medicure, RPG Lifesciences, SMS Pharmaceuticals, Nectar Lifesciences and Marksans Pharma from the S&P BSE Healthcare index were up in the range of 4% to 12% on the BSE.
At 11:25 am; Nifty Pharma index, the largest gainer among sectoral indices, was up 1.4% at 10,530 on the NSE. In comparison, the Nifty 50 index was up 0.15% at 11,697.
In past 14 trading days, the pharma index has outperformed the market by surging 15% as compared to a 2.3% rise in the benchmark index.
Sun Pharma hits a fresh 52-week high of Rs 669, up 2% on the NSE on reports that the US Food and Drug Administration (FDA) completed auditing the company’s Halol plant with on observations. In past three months, the stock rallied 39% as compared to 10% rise in the Nifty 50 index.
On June 12, 2018, Sun Pharma had received the Establishment Inspection Report (EIR) from the US FDA for the inspection conducted at its Halol facility (Gujarat, India) during the period February 12-23, 2018.
“The agency concluded that the inspection now closed and the issues contained in the Warning Letter issued in December 2015 have been addressed,” the company had said.
Dr Reddy’s Laboratories too hit a 52-week high of Rs 2,612, up 5%, extending its Friday’s 5% surge on the BSE.
The company on August 23 had received an EIR from the US health regulator for its Srikakulam facility in Andhra Pradesh. The Srikakulam unit manufactures active pharmaceutical ingredients (APIs). The EIR from the USFDA indicates closure of the audit of the plant, Dr Reddy's Labs had said in a BSE filing.
In an earlier filing on June 2, 2018, the company had said that the audit of the Srikakulam plant (SEZ) by USFDA had been completed with no observations.
Sun Pharmaceutical Industries, Dr Reddys Laboratories, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Abbott India, Merck, Sanofi India and GlaxoSmithKline Pharmaceuticals were among 11 stock that hit their respective 52-week highs on Monday.
Hikal, Poly Medicure, RPG Lifesciences, SMS Pharmaceuticals, Nectar Lifesciences and Marksans Pharma from the S&P BSE Healthcare index were up in the range of 4% to 12% on the BSE.
At 11:25 am; Nifty Pharma index, the largest gainer among sectoral indices, was up 1.4% at 10,530 on the NSE. In comparison, the Nifty 50 index was up 0.15% at 11,697.
In past 14 trading days, the pharma index has outperformed the market by surging 15% as compared to a 2.3% rise in the benchmark index.
Sun Pharma hits a fresh 52-week high of Rs 669, up 2% on the NSE on reports that the US Food and Drug Administration (FDA) completed auditing the company’s Halol plant with on observations. In past three months, the stock rallied 39% as compared to 10% rise in the Nifty 50 index.
On June 12, 2018, Sun Pharma had received the Establishment Inspection Report (EIR) from the US FDA for the inspection conducted at its Halol facility (Gujarat, India) during the period February 12-23, 2018.
“The agency concluded that the inspection now closed and the issues contained in the Warning Letter issued in December 2015 have been addressed,” the company had said.
Dr Reddy’s Laboratories too hit a 52-week high of Rs 2,612, up 5%, extending its Friday’s 5% surge on the BSE.
The company on August 23 had received an EIR from the US health regulator for its Srikakulam facility in Andhra Pradesh. The Srikakulam unit manufactures active pharmaceutical ingredients (APIs). The EIR from the USFDA indicates closure of the audit of the plant, Dr Reddy's Labs had said in a BSE filing.
In an earlier filing on June 2, 2018, the company had said that the audit of the Srikakulam plant (SEZ) by USFDA had been completed with no observations.
| COMPANY | LATEST | 52 WK HIGH | PREV HIGH | PREV DATE |
| ABBOTT INDIA | 8575.00 | 8690.00 | 8690.00 | 31-Aug-18 |
| ALBERT DAVID | 734.15 | 736.90 | 615.95 | 31-Aug-18 |
| DR REDDY'S LABS | 2600.95 | 2612.00 | 2611.80 | 24-Jan-18 |
| GLAXOSMI. PHARMA | 3500.00 | 3520.00 | 3470.00 | 31-Aug-18 |
| GLENMARK PHARMA. | 672.50 | 676.00 | 671.35 | 31-Aug-18 |
| HIKAL | 182.25 | 185.60 | 176.90 | 23-Apr-18 |
| J B CHEM & PHARM | 341.90 | 351.00 | 350.00 | 31-Aug-18 |
| MERCK | 3487.75 | 3549.00 | 3547.75 | 31-Aug-18 |
| SANOFI INDIA | 6475.00 | 6680.00 | 6598.75 | 28-Aug-18 |
| SUN PHARMA.INDS. | 665.60 | 665.70 | 658.90 | 31-Aug-18 |
| TORRENT PHARMA. | 1851.00 | 1851.00 | 1825.65 | 31-Aug-18 |
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%